S&P 500   4,145.19
DOW   32,803.47
QQQ   324.52
What to Expect from the Markets in a Recession
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   324.52
What to Expect from the Markets in a Recession
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   324.52
What to Expect from the Markets in a Recession
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   324.52
What to Expect from the Markets in a Recession
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
China July exports rise, with trade surplus at record-high
Electric Vehicles Can Drive Alcoa Stock Higher
What's in Democrats' big bill? Climate, health care, savings
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
NASDAQ:SMMT

Summit Therapeutics (SMMT) Price Target & Analyst Ratings

$0.89
-0.05 (-5.32%)
(As of 08/5/2022 03:59 PM ET)
Add
Compare
Today's Range
$0.89
$0.93
50-Day Range
$0.89
$1.33
52-Week Range
$0.88
$8.39
Volume
2,429 shs
Average Volume
143,605 shs
Market Capitalization
$87.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Summit Therapeutics Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 1 Analyst Ratings

Consensus Analyst Price Target

N/A

TypeCurrent
8/8/21 to 8/8/22
1 Month Ago
7/9/21 to 7/9/22
3 Months Ago
5/10/21 to 5/10/22
1 Year Ago
8/8/20 to 8/8/21
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Predicted UpsideN/AN/AN/AN/A
Get Summit Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.


SMMT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SMMT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Summit Therapeutics Stock vs. The Competition

TypeSummit TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.71
2.50
Consensus RatingHoldBuyHold
Predicted Upside516.79% Upside18.64% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
283
58.71%
Underperform Votes
199
41.29%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
840
68.74%
Avg. Underperform Votes
382
31.26%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/6/2021HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Arce
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
(Data available from 8/8/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Summit Therapeutics Price Target - Frequently Asked Questions

What is Summit Therapeutics's consensus rating?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Summit Therapeutics stock is Hold based on the current 1 hold rating for SMMTthe . Learn more on SMMT's analyst rating history.

Do Wall Street analysts like Summit Therapeutics more than its competitors?

Analysts like Summit Therapeutics less than other Medical companies. The consensus rating for Summit Therapeutics is Hold while the average consensus rating for medical companies is Buy. Learn more on how SMMT compares to other companies.

Do MarketBeat users like Summit Therapeutics more than its competitors?

MarketBeat users like Summit Therapeutics less than other Medical companies. 58.71% of MarketBeat users gave Summit Therapeutics an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.


Stock Ratings Reports and Tools

This page (NASDAQ:SMMT) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.